Physician profile
Jon D Studinger
NPI 1912672544
$7,728.47
in general payments reported to CMS, 2019-2025
31 companies · $2,510 in 2025
The $2,510 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,467 · 2023: $1,573 · 2024: $2,179 · 2025: $2,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,911 · Education: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,911.20 |
| Education | $350.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,159.31 | 2022-2025 | Tezspire, Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $872.08 | 2022-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $699.28 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $678.29 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $528.34 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Genzyme Corporation | $333.70 | 2022-2025 | |
| Mylan Specialty L.P. | $305.99 | 2022-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $303.08 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| Jazz Pharmaceuticals INC. | $250.64 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $187.98 | 2024-2025 | |
| Axsome Therapeutics, INC. | $186.38 | 2024-2025 | Sunosi |
| Viatris Specialty LLC | $164.32 | 2025 | Yupelri |
| Avadel Cns Pharmaceuticals, LLC | $142.59 | 2024-2025 | Lumryz |
| Amgen INC. | $131.48 | 2022-2025 | Tezspire |
| Insmed, INC. | $115.91 | 2022-2025 | Brinsupri, Arikayce |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $97.73 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $83.37 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Verona Pharma, INC. | $79.43 | 2025 | Ohtuvayre |
| Resmed Corp | $69.83 | 2025 | |
| Philips North America LLC | $62.20 | 2024-2025 | Vest Therapy Und, (8874) Incourage |
| Harmony Biosciences LLC | $52.84 | 2022-2025 | |
| 3b Medical, INC. | $51.35 | 2024-2025 | Luna |
| United Therapeutics Corporation | $46.82 | 2022-2025 | Tyvaso |
| Genentech USA, INC. | $23.55 | 2025 | Xolair |
| Vapotherm INC | $16.34 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.38 | 2023 | Ultomiris |
| Pfizer INC. | $15.37 | 2025 | |
| Paratek Pharmaceuticals, INC. | $15.32 | 2022 | |
| Phadia US INC. | $14.90 | 2024 | Immunocap |
| Teva Pharmaceuticals USA, INC. | $12.57 | 2022 | |
| Covis Pharma Gmbh | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Studinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.